: Based on the WHO classification, which distinguishes between well-differentiated tumors (NET G1, G2, G3) and poorly differentiated neuroendocrine carcinomas (NEC). Diagnostic Tools : Endoscopy : For localization and biopsy.
: Use of Somatostatin analogs (Lanreotide/Octreotide) to control secretions and tumor growth.
: Focused on endoscopic management and screening.
: Measurement of Chromogranin A (CgA) and 5-HIAA (for carcinoid syndrome).
: Peptide Receptor Radionuclide Therapy for advanced cases. Recommended Sources for PDF Downloads
: Based on the WHO classification, which distinguishes between well-differentiated tumors (NET G1, G2, G3) and poorly differentiated neuroendocrine carcinomas (NEC). Diagnostic Tools : Endoscopy : For localization and biopsy.
: Use of Somatostatin analogs (Lanreotide/Octreotide) to control secretions and tumor growth.
: Focused on endoscopic management and screening.
: Measurement of Chromogranin A (CgA) and 5-HIAA (for carcinoid syndrome).
: Peptide Receptor Radionuclide Therapy for advanced cases. Recommended Sources for PDF Downloads
%!s(int=2026) © %!d(string=Peak Lantern)Nithra Edu Solutions India Pvt Ltd. All rights reserved